Search

Background: Papulopustular rosacea (PPR) is a chronic inflammatory disease with a significant impact on facial aesthetics. An impaired skin barrier is an important factor in the development and exacerbation of PPR. Tranexamic acid (TXA) has immune regulatory and anti‐inflammatory effects, inhibits angiogenesis and endothelial hyperplasia, and promotes skin barrier repair. Aims: We investigated the efficacy and safety of oral TXA for PPR treatment. Patients/Methods: In total, 70 patients were randomly assigned to receive traditional therapy plus oral TXA or traditional therapy alone for 8 weeks, with a 4‐week follow‐up period. The subjective improvement in rosacea was assessed using the clinical erythema assessment (CEA), investigator's global assessment (IGA), patient self‐assessment (PSA) score, rosacea‐specific quality of life (RQoL) score, and global aesthetic improvement score (GAIS). An objective improvement in rosacea was assessed using skin hydration, trans‐epidermal water loss (TEWL), clinical photography, and an eight spectrum facial imager. Results: CEA/IGA/PSA, dryness, and RQoL scores were significantly lower and GAIS was higher in the TXA group than in the traditional therapy group. Furthermore, oral TXA significantly improved skin barrier function, increased skin hydration, and decreased TEWL, with no significant side effects. Notably, we observed better outcomes and a greater improvement in skin barrier function with TXA treatment in patients with dry‐type rosacea than in patients with oily skin. Conclusions: The addition of oral TXA to traditional therapy can lead to rapid and effective improvements in PPR, which may be attributed to improvements in skin barrier function. [ABSTRACT FROM AUTHOR]

Background: Vaccination is an important method for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) transmission. There is currently a lack of real‐world clinical data regarding the safety and efficacy of coronavirus disease 2019 (COVID‐19) vaccines with respect to plaque psoriasis treatment involving tumor necrosis factor‐α (TNF‐α) and interleukin‐17A (IL‐17A) inhibitors. Methods: We longitudinally analyzed 152 patients with plaque psoriasis, 86 of whom received two doses of inactivated COVID‐19 vaccine (either BBIBP‐CorV or CoronaVac). Comparisons were made between patients undergoing treatment with biologics (TNF‐ α inhibitors or IL‐17A inhibitors) or acitretin. Routine blood tests were used to assess safety; the psoriasis area and severity index (PASI) and dermatology life quality index (DLQI) were used to assess efficacy. Results: After inactivated COVID‐19 vaccination, biologics retained considerable advantages in terms of improving skin lesions (measured by PASI) and quality of life (measured by DLQI), compared with conventional treatment (p < 0.05 and p < 0.01, respectively). Routine blood tests and hepatorenal function analyses suggested that inactivated SARS‐CoV‐2 vaccines did not alter the safety of biologics treatment (p > 0.05). Conclusions: Inactivated SARS‐CoV‐2 vaccines do not have significant impacts on the safety and efficacy of biologics (TNF‐α inhibitors or IL‐17A inhibitors) in patients with moderate to severe plaque psoriasis. [ABSTRACT FROM AUTHOR]